14611-52-0 | Benzeneethanamine, N,α-dimethyl-N-2-propyn-1-yl-, hydrochloride (1:1), (αR)-

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$42.00	$29.00
250mg	98%	in stock	$78.00	$54.00
500mg	98%	in stock	$120.00	$84.00
1g	98%	in stock	$179.00	$126.00

Description

• Catalog Number: AA64215
• Chemical Name: Benzeneethanamine, N,α-dimethyl-N-2-propyn-1-yl-, hydrochloride (1:1), (αR)-
• CAS Number: 14611-52-0
• Molecular Formula: C13H18ClN
• Molecular Weight: 223.7417
• MDL Number: MFCD00069299
• SMILES: C[C@@H](N(CC#C)C)Cc1ccccc1.Cl

Computed Properties

• Complexity: 195
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 15
• Hydrogen Bond Acceptor Count: 1
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4

Literature

• Inhibition of monoamine oxidase-B by selegiline reduces cigarette smoke-induced oxidative stress and inflammation in airway epithelial cells.

  Toxicology letters 20170215

• Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.

  Chemico-biological interactions 20150325

• Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.

  Journal of neural transmission (Vienna, Austria : 1996) 20150201

• Deprenyl enhances the teratogenicity of hydroxyurea in organogenesis stage mouse embryos.

  Toxicological sciences : an official journal of the Society of Toxicology 20130801

• Comparison of the cutaneous iontophoretic delivery of rasagiline and selegiline across porcine and human skin in vitro.

  International journal of pharmaceutics 20121115

• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neuroblastic apoptosis in the subventricular zone is caused by 1-methy-4-phenylpiridinium (MPP(+)) converted from MPTP through MAO-B.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20121101

• Retention rate of selegiline in early Parkinson's disease: a retrospective survey.

  International journal of clinical practice 20121001

• Involvement of monoamine oxidase B on models of postoperative and neuropathic pain in mice.

  European journal of pharmacology 20120905

• Cerebral blood flow and freezing of gait in Parkinson's disease.

  Acta neurologica Scandinavica 20120901

• Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20120901

• Modulations of brain amines and dopaminergic behavior by a novel, reversible and selective MAO-B inhibitor.

  Brain research 20120827

• Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.

  British journal of clinical pharmacology 20120801

• Activity-based probes for studying the activity of flavin-dependent oxidases and for the protein target profiling of monoamine oxidase inhibitors.

  Angewandte Chemie (International ed. in English) 20120709

• AIRE-induced apoptosis is associated with nuclear translocation of stress sensor protein GAPDH.

  Biochemical and biophysical research communications 20120622

• Subthalamic deep brain stimulation at individualized frequencies for Parkinson disease.

  Neurology 20120612

• Cerebral ischemia-reperfusion induces GAPDH S-nitrosylation and nuclear translocation.

  Biochemistry. Biokhimiia 20120601

• Cardiovascular baroreceptor activity and selective inhibition of monoamine oxidase.

  European journal of pharmacology 20120515

• Basic cell physiological activities (cell adhesion, chemotaxis and proliferation) induced by selegiline and its derivatives in Mono Mac 6 human monocytes.

  Journal of neural transmission (Vienna, Austria : 1996) 20120501

• Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures.

  The Journal of clinical psychiatry 20120501

• Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.

  Journal of neural transmission (Vienna, Austria : 1996) 20120401

• In vitro-in vivo correlation for intrinsic clearance for CP-409,092 and sumatriptan: a case study to predict the in vivo clearance for compounds metabolized by monoamine oxidase.

  Xenobiotica; the fate of foreign compounds in biological systems 20120401

• In vivo evaluation in cynomolgus monkey brain and metabolism of [¹⁸F]fluorodeprenyl: a new MAO-B pet radioligand.

  Synapse (New York, N.Y.) 20120401

• 8-Substituted 3-arylcoumarins as potent and selective MAO-B inhibitors: synthesis, pharmacological evaluation, and docking studies.

  ChemMedChem 20120305

• Selegiline transdermal system (STS) as an aid for smoking cessation.

  Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 20120301

• Induction of adipose-derived stem cell into motoneuron-like cells using selegiline as preinducer.

  Brain research 20120227

• Tyrosine hydroxylase deficiency in Taiwanese infants.

  Pediatric neurology 20120201

• The effect of selegiline on total scavenger capacity and liver fat content: a preliminary study in an animal model.

  Journal of neural transmission (Vienna, Austria : 1996) 20120101

• Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20120101

• Selegiline: a reappraisal of its role in Parkinson disease.

  Clinical neuropharmacology 20120101

• Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk.

  Toxicology 20111218

• In vivo imaging of astrocytosis in Alzheimer's disease: an ¹¹C-L-deuteriodeprenyl and PIB PET study.

  European journal of nuclear medicine and molecular imaging 20111201

• PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.

  Experimental neurology 20111201

• Predicting successful 24-hr quit attempt in a smoking cessation intervention.

  Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 20111101

• Pharmacoresistant convulsions and visual hallucinations around two weeks after selegiline overdose: a case report.

  Pharmacopsychiatry 20111101

• Synthesis of three novel fluorine-18 labeled analogues of L-deprenyl for positron emission tomography (PET) studies of monoamine oxidase B (MAO-B).

  Journal of medicinal chemistry 20111027

• Trans-differentiation of the adipose tissue-derived stem cells into neuron-like cells expressing neurotrophins by selegiline.

  Iranian biomedical journal 20111001

• Selegiline-functionalized, PEGylated poly(alkyl cyanoacrylate) nanoparticles: Investigation of interaction with amyloid-β peptide and surface reorganization.

  International journal of pharmaceutics 20110920

• Effects of selegiline, a monoamine oxidase B inhibitor, on differentiation of P19 embryonal carcinoma stem cells, into neuron-like cells.

  In vitro cellular & developmental biology. Animal 20110901

• Transdermal delivery of selegiline from alginate-Pluronic composite thermogels.

  International journal of pharmaceutics 20110830

• CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.

  Brain research 20110823

• Inhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20110801

• MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins.

  Bioorganic & medicinal chemistry letters 20110715

• The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment.

  Acta neurologica Scandinavica 20110701

• Differences in smoking expectancies in smokers with and without a history of major depression.

  Addictive behaviors 20110401

• Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times.

  Parkinsonism & related disorders 20110301

• Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency.

  Journal of child neurology 20110201

• Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease.

  Parkinsonism & related disorders 20110201

• MAO inhibitors.

  Cleveland Clinic journal of medicine 20110201

• The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species.

  Journal of molecular biology 20110107

• Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.

  Neurochemistry international 20110101

• Selegiline and rasagiline: twins or distant cousins?

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20110101

• Pharmacotherapy for late-life depression.

  The Journal of clinical psychiatry 20110101

• Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro.

  BMC pharmacology 20110101

• Elevated [11C]-D-deprenyl uptake in chronic Whiplash Associated Disorder suggests persistent musculoskeletal inflammation.

  PloS one 20110101

• Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.

  PloS one 20110101

• The pharmacology of selegiline.

  International review of neurobiology 20110101

• Selective inhibitors of monoamine oxidase type B and the 'cheese effect'.

  International review of neurobiology 20110101

• Supplementation of deprenyl attenuates age associated alterations in rat cerebellum.

  Molecular biology reports 20101201

• Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.

  Journal of clinical pharmacology 20101201

• R-deprenyl: pharmacological spectrum of its activity.

  Neurochemical research 20101201

• MAO inhibitors: risks, benefits, and lore.

  Cleveland Clinic journal of medicine 20101201

• Ring opening of pymisyl-protected aziridines with organocuprates.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20101102

• Transdermal iontophoretic delivery of selegiline hydrochloride, in vitro.

  Journal of drug targeting 20101101

• Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.

  Progress in neurobiology 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Orthostatic hypotension: a non-motor complication assessment in 82 patients with idiopathic Parkinson's disease in Phramongkutklao Hospital.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20101101

• The fabulous neuroprotection of selegiline: memoir and prospectus.

  Journal of child neurology 20101001

• Clozapine for medication-related pathological gambling in Parkinson disease.

  Movement disorders : official journal of the Movement Disorder Society 20100915

• Age-related protective effect of deprenyl on changes in the levels of diagnostic marker enzymes and antioxidant defense enzymes activities in cerebellar tissue in Wistar rats.

  Cell stress & chaperones 20100901

• HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20100901

• Changes in smoking expectancies in abstinent, reducing, and non-abstinent participants during a pharmacological trial for smoking cessation.

  Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 20100901

• Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy.

  Addiction (Abingdon, England) 20100901

• [The feasibility of synthetic enhancer substances for preventive nanotherapy].

  Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20100901

• Slowing the decline.

  Nature 20100826

• Cytoprotective effect of (-)-deprenyl, (-)desmethyl-deprenyl and (-)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells.

  Journal of neural transmission (Vienna, Austria : 1996) 20100601

• A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage.

  Biological psychiatry 20100501

• Marked improvement in Segawa syndrome after L-dopa and selegiline treatment.

  Pediatric neurology 20100501

• [General anaesthesia for neurological diseases].

  Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS 20100501

• Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo.

  Cellular and molecular neurobiology 20100401

• Manganese neurotoxic time course is not influenced by L-deprenyl systemic treatment: influence of L-deprenyl in manganese neurotoxic time course.

  Brain research 20100304

• Selegiline is an efficient and potent inducer for bone marrow stromal cell differentiation into neuronal phenotype.

  Neurological research 20100301

• A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers.

  Drug and alcohol dependence 20100301

• [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].

  Fortschritte der Neurologie-Psychiatrie 20100301

• Cognitive aspects of congenital learned helplessness and its reversal by the monoamine oxidase (MAO)-B inhibitor deprenyl.

  Neurobiology of learning and memory 20100201

• (-)-Deprenyl inhibits vascular hyperpermeability after hemorrhagic shock.

  Shock (Augusta, Ga.) 20100101

• Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.

  Clinical neuropharmacology 20100101

• Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.

  Clinical neuropharmacology 20100101

• Frontotemporal dementia and pharmacologic interventions.

  The Journal of neuropsychiatry and clinical neurosciences 20100101

• Transdermal selegiline in patients receiving electroconvulsive therapy.

  Psychosomatics 20100101

• Electropharmacograms of rasagiline, its metabolite aminoindan and selegiline in the freely moving rat.

  Neuropsychobiology 20100101

• Zonisamide attenuates MPTP neurotoxicity in marmosets.

  Journal of pharmacological sciences 20100101

• A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.

  Movement disorders : official journal of the Movement Disorder Society 20091215

• Selegiline and oxidative stress in HIV-associated cognitive impairment.

  Neurology 20091208

• Acidic vesicles of the endo-exocytic pathways as targets for some anti-monoamine oxidase drugs.

  Metabolic brain disease 20091201

• [Severe apathy following head injury: improvement with Selegiline treatment].

  Neuro-Chirurgie 20091201

• [Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal].

  Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20091201

• Effect of deprenyl on free radical oxidation in rat brain during immobilization stress.

  Bulletin of experimental biology and medicine 20091201

• Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort.

  Neurology 20091103

• Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.

  Journal of neural transmission (Vienna, Austria : 1996) 20091101

• Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.

  The Cochrane database of systematic reviews 20091007

• Transdermal permeation of selegiline from hydrogel-membrane drug delivery systems.

  International journal of pharmaceutics 20091001

• (-)Deprenyl-N-oxide, a (-)deprenyl metabolite, is cytoprotective after hypoxic injury in PC12 cells, or after transient brain ischemia in gerbils.

  Journal of the neurological sciences 20090815

• Serotonin toxicity caused by moclobemide too soon after paroxetine-selegiline.

  Journal of the Chinese Medical Association : JCMA 20090801

• Selegiline shortage: Causes and costs of a generic drug shortage.

  Neurology 20090721

• Selegiline transdermal system: a novel treatment option for major depressive disorder.

  Expert opinion on pharmacotherapy 20090701

• A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.

  Bioorganic & medicinal chemistry letters 20090615

• Teasing apart drug treatments and individual symptoms in narcolepsy.

  Sleep medicine 20090601

• Short-term erythrosine B-induced inhibition of the brain regional serotonergic activity suppresses motor activity (exploratory behavior) of young adult mammals.

  Pharmacology, biochemistry, and behavior 20090601

• Involvement of protein trafficking in deprenyl-induced alpha-secretase activity regulation in PC12 cells.

  European journal of pharmacology 20090521

• Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area.

  The international journal of neuropsychopharmacology 20090501

• Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301.

  Clinical pharmacology and therapeutics 20090501

• Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP.

  Journal of pharmacological sciences 20090501

• MAO-B inhibitor know-how: back to the pharm.

  Neurology 20090414

• Hyperserotonergic phenotype after monoamine oxidase inhibition in larval zebrafish.

  Journal of neurochemistry 20090401

• Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis.

  Neurotoxicity research 20090401

• 'Bad guys' among the antiparkinsonian drugs.

  Psychiatria Danubina 20090301

• Antioxidant and antiapoptotic activities of deprenyl and estradiol co-administration in aged rat kidney.

  Acta biologica Hungarica 20090301

• Neuroprotection by rasagiline in thiamine deficient rats.

  Brain research 20090223

• MPTP and MPP+ target specific aminergic cell populations in larval zebrafish.

  Journal of neurochemistry 20090201

• [Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].

  Ideggyogyaszati szemle 20090130

• A case report of high-dose transdermal selegiline in the treatment of major depressive disorder.

  Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20090101

• Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits.

  European review for medical and pharmacological sciences 20090101

• A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion.

  BMC clinical pharmacology 20090101

• (-)-Deprenyl inhibits thermal injury-induced apoptotic signaling and hyperpermeability in microvascular endothelial cells.

  Journal of burn care & research : official publication of the American Burn Association 20090101

• Serum prolactin as a tool for the follow-up of treated DHPR-deficient patients.

  Journal of inherited metabolic disease 20081201

• Antidepressant activity of curcumin: involvement of serotonin and dopamine system.

  Psychopharmacology 20081201

• 1-Methyl-4-phenyl-pyridinium ion-induced oxidative stress, c-Jun phosphorylation and DNA fragmentation factor-45 cleavage in SK-N-SH cells are averted by selegiline.

  Neurochemistry international 20081201

• The effect of short-term administration of (-)-deprenyl and isatin on the expressions of some genes in the mouse brain cortex.

  Medical science monitor : international medical journal of experimental and clinical research 20081201

• Neural progenitor cells are protected against MPTP by MAO-B inhibitors.

  Neurotoxicology 20081101

• Orally disintegrating selegiline for the treatment of Parkinson's disease.

  Expert opinion on pharmacotherapy 20081101

• Protective effects of deprenyl in transient cerebral ischemia in rats.

  The Chinese journal of physiology 20081031

• Apomorphine offers new insight into dopaminergic neuron vulnerability in mesencephalic cultures.

  Neuropharmacology 20081001

• Pharmacological treatment in moderate-to-severe Alzheimer's disease.

  Expert opinion on pharmacotherapy 20081001

• Detection of levorotatory methamphetamine and levorotatory amphetamine in urine after ingestion of an overdose of selegiline.

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20081001

• [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].

  Fortschritte der Neurologie-Psychiatrie 20081001

• [Motor symptoms in Parkinson disease].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20080925

• Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

  Neurology 20080812

• Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35).

  Behavioural brain research 20080719

• Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration.

  Journal of neurochemistry 20080601

• Study of high deprenyl dose on the preimplantation embryo development and lymphocyte DNA in rat.

  General physiology and biophysics 20080601

• Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells.

  Neurological research 20080501

• The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.

  British journal of pharmacology 20080501

• Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.

  Movement disorders : official journal of the Movement Disorder Society 20080415

• Selegilin exerts antidepressant-like effects during the forced swim test in adrenocorticotropic hormone-treated rats.

  Journal of pharmacological sciences 20080401

• Optimization and validation of a dissolution test for selegiline hydrochloride tablets by a novel rapid HPLC assay using a monolithic stationary phase.

  Journal of pharmaceutical and biomedical analysis 20080313

• Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

  Human psychopharmacology 20080301

• Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice.

  The Journal of pharmacology and experimental therapeutics 20080301

• Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production.

  Neurotoxicology 20080301

• [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].

  Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20080301

• [Role of apoptosis in the kidney after reperfusion].

  Orvosi hetilap 20080217

• Transdermal selegiline: new opportunity for managing depression.

  The Journal of the American Osteopathic Association 20080201

• [The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life].

  Ideggyogyaszati szemle 20080130

• Parallel analysis of stimulants in saliva and urine by gas chromatography/mass spectrometry: perspectives for 'in competition' anti-doping analysis.

  Analytica chimica acta 20080114

• The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.

  Journal of affective disorders 20080101

• Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.

  Journal of neural transmission (Vienna, Austria : 1996) 20080101

• Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets.

  Psychopharmacology 20080101

• Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic.

  Journal of psychiatric practice 20080101

• Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant.

  Arzneimittel-Forschung 20080101

• Paradoxical effects of adenosine receptor ligands on hydroxyl radical generation by L-DOPA in the rat striatum.

  Pharmacological reports : PR 20080101

• Antagonistic effect of low deprenyl dose on the preimplantation embryo development in rat.

  Bratislavske lekarske listy 20080101

• Possible new antiaging strategies related to neuroendocrine-immune interactions.

  Neuroimmunomodulation 20080101

• Differential effects of selegiline on glucose synthesis in rabbit kidney-cortex tubules and hepatocytes. In vitro and in vivo studies.

  Chemico-biological interactions 20071215

• In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human.

  Drug metabolism and disposition: the biological fate of chemicals 20071201

• Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.

  Pharmacotherapy 20071201

• Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.

  The Journal of clinical psychiatry 20071201

• Deprenyl treatment attenuates long-term pre- and post-synaptic changes evoked by chronic methamphetamine.

  European journal of pharmacology 20071114

• Gestational exposure to nicotine and monoamine oxidase inhibitors influences cocaine-induced locomotion in adolescent rats.

  Psychopharmacology 20071101

• Bystander effects of ionizing radiation can be modulated by signaling amines.

  Environmental research 20071001

• Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.

  Journal of clinical pharmacology 20071001

• Zydis selegiline in the management of Parkinson's disease.

  Expert opinion on pharmacotherapy 20071001

• A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment.

  Neurology 20070925

• Lost in translation: again, another failed neuroprotection trial.

  Neurology 20070925

• Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?

  Journal of psychiatry & neuroscience : JPN 20070901

• Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.

  Clinical therapeutics 20070901

• A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.

  Journal of neuroscience methods 20070815

• Selegiline transdermal system: current awareness and promise.

  Progress in neuro-psychopharmacology & biological psychiatry 20070815

• Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers.

  Journal of clinical pharmacology 20070801

• Low plasma uric acid level in Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20070615

• The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates.

  Molecular pharmacology 20070601

• Antioxidant effects of selegiline in oxidative stress induced by iron neonatal treatment in rats.

  Neurochemical research 20070601

• Therapeutic advances in narcolepsy.

  Sleep medicine 20070601

• Treatment-resistant depression: response to low-dose transdermal but not oral selegiline.

  Journal of clinical psychopharmacology 20070601

• Transdermal selegiline.

  Drugs of today (Barcelona, Spain : 1998) 20070601

• Rasagiline as a therapy for Parkinson's disease (PD).

  The American journal of geriatric pharmacotherapy 20070601

• Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.

  Journal of neuroscience research 20070515

• The role of selegiline in the treatment of negative symptoms associated with schizophrenia.

  The Annals of pharmacotherapy 20070501

• Bacopa monniera prevents from aluminium neurotoxicity in the cerebral cortex of rat brain.

  Journal of ethnopharmacology 20070420

• Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET.

  Journal of the neurological sciences 20070415

• Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease.

  Current medical research and opinion 20070401

• Translating the evidence on atypical depression into clinical practice.

  The Journal of clinical psychiatry 20070401

• P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine.

  Drug metabolism and pharmacokinetics 20070401

• Involvement of cytochromes P450 2D6, 2B6 and 2C19 in the metabolism of (-)-deprenyl and N-methyl,N-propargylphenylethylamine.

  Drug metabolism letters 20070401

• Oxygen-glucose deprivation-induced changes in organotypic cultures of the rat hippocampus.

  Ideggyogyaszati szemle 20070330

• Metabolism of N-methyl, N-propargylphenylethylamine: studies with human liver microsomes and cDNA expressed cytochrome P450 (CYP) enzymes.

  Cellular and molecular neurobiology 20070301

• Selegiline and blood pressure in patients with Parkinson's disease.

  Acta neurologica Scandinavica 20070201

• Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications.

  Journal of clinical pharmacology 20070201

• Antioxidants and Alzheimer's disease: time to stop feeding vitamin E to dementia patients?

  International psychogeriatrics 20070201

• Separation of enantiomers of deprenyl with various CDs in CE and the effect of enantiomer migration order on enantiomeric impurity determination of selegiline in active ingredients and tablets.

  Electrophoresis 20070201

• Psychopharmacology column: why choose selegiline transdermal system for refractory depression?

  Issues in mental health nursing 20070201

• Management of sexual dysfunction due to antipsychotic drug therapy.

  The Cochrane database of systematic reviews 20070124

• Improvement of mouse brain mitochondrial function after deprenyl treatment.

  Neuroscience 20070119

• Mitogen activated protein kinase and protein kinase C activation mediate promotion of sAPPalpha secretion by deprenyl.

  Neurochemistry international 20070101

• Chronic (-)-deprenyl administration attenuates dendritic developmental impairment induced by early social isolation in the rat.

  Developmental neuroscience 20070101

• Seligiline transdermal system in depression.

  Expert opinion on pharmacotherapy 20070101

• Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour.

  CNS spectrums 20070101

• Selegiline transdermal system: in the treatment of major depressive disorder.

  Drugs 20070101

• The effect of l-deprenyl on tissue mRNA expressions of NOS isoforms and NO levels in an experimental diabetes mellitus model.

  Journal of neural transmission (Vienna, Austria : 1996) 20070101

• Selegiline transdermal system in major depressive disorder: profile report.

  CNS drugs 20070101

• Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

  Clinical neuropharmacology 20070101

• Suppression of apoptosis and oxidative stress by deprenyl and estradiol in aged rat liver.

  Acta histochemica 20070101

• Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.

  Drugs & aging 20070101

• Selegiline orally disintegrating tablets in patients with Parkinson disease and 'wearing off' symptoms.

  Clinical neuropharmacology 20070101

• Placebo response in Parkinson trials using patient diaries: sites do matter.

  Clinical neuropharmacology 20070101

• A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.

  Clinical neuropharmacology 20070101

• Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers.

  Journal of neural transmission. Supplementum 20070101

• Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse.

  Journal of neural transmission. Supplementum 20070101

• Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.

  Psychopharmacology bulletin 20070101

• Commentary on the treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.

  Psychopharmacology bulletin 20070101

• Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090.

  HIV clinical trials 20070101

• Simultaneous determination of selegiline and desmethylselegiline in human body fluids by headspace solid-phase microextraction and gas chromatography-mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061205

• Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence.

  Drug and alcohol dependence 20061201

• Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.

  Journal of clinical psychopharmacology 20061201

• L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action.

  Pharmacology, biochemistry, and behavior 20061201

• The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.

  Current Alzheimer research 20061201

• Monoamine oxidase inhibitory coumarins from the aerial parts of Dictamnus albus.

  Archives of pharmacal research 20061201

• A new application of pre-normalized principal component analysis for improvement of image quality and clinical diagnosis in human brain PET studies--clinical brain studies using [11C]-GR205171, [11C]-L-deuterium-deprenyl, [11C]-5-Hydroxy-L-Tryptophan, [11C]-L-DOPA and Pittsburgh Compound-B.

  NeuroImage 20061101

• Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases.

  Current drug targets 20061101

• Acute effects of moclobemide and deprenyl on 5-HT synthesis rates in the rat brain: An autoradiographic study.

  Brain research bulletin 20061016

• Parkinsonism-hyperpyrexia syndrome: the role of electroconvulsive therapy.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20061001

• A systematic review of research on strategies for the management of antipsychotic-induced sexual dysfunction: high-level evidence is needed.

  The Journal of clinical psychiatry 20061001

• Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases.

  Parkinsonism & related disorders 20060901

• Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.

  The Journal of clinical psychiatry 20060901

• The combined use of human neural and liver cell lines and mouse hepatocytes improves the predictability of the neurotoxicity of selected drugs.

  Toxicology letters 20060820

• Cytoprotective effect of two synthetic enhancer substances, (-)-BPAP and (-)-deprenyl, on human brain capillary endothelial cells and rat PC12 cells.

  Life sciences 20060808

• (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity.

  European journal of pharmacology 20060807

• Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.

  Journal of clinical pharmacology 20060801

• Effects of subchronic treatment with selegiline on L-DOPA-induced increase in extracellular dopamine level in rat striatum.

  Journal of pharmacological sciences 20060801

• Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder.

  Journal of child and adolescent psychopharmacology 20060801

• A new way to deliver psychiatric meds.

  Behavioral healthcare 20060801

• Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy.

  The Cochrane database of systematic reviews 20060719

• [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl].

  Orvosi hetilap 20060709

• L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.

  Neurochemistry international 20060701

• Neuroprotective role of Bacopa monniera extract against aluminium-induced oxidative stress in the hippocampus of rat brain.

  Neurotoxicology 20060701

• Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl.

  Neurobiology of disease 20060701

• Transdermal selegiline: a novel MAOI formulation for depression.

  Journal of psychosocial nursing and mental health services 20060701

• Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

  Journal of pharmacokinetics and pharmacodynamics 20060601

• High-throughput screening for monoamine oxidase-A and monoamine oxidase-B inhibitors using one-step fluorescence assay.

  Acta pharmacologica Sinica 20060601

• Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.

  Neurology 20060523

• Transdermal selegiline (Emsam).

  The Medical letter on drugs and therapeutics 20060522

• Initial pharmacotherapy in a population of veterans with Parkinson disease.

  Neurology 20060509

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Leading the way: advances in the diagnosis, treatment, and management of neuropsychiatric illnesses.

  CNS spectrums 20060501

• Transdermal selegiline: the new generation of monoamine oxidase inhibitors.

  CNS spectrums 20060501

• Why the transdermal delivery of selegiline (6 mg/24 hr) obviates the need for a dietary restriction on tyramine.

  Journal of psychiatric practice 20060501

• Amphetamine-induced locomotor activity is reduced in mice following MPTP treatment but not following selegiline/MPTP treatment.

  Pharmacology, biochemistry, and behavior 20060501

• High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users.

  Journal of analytical toxicology 20060501

• The necessity of having a proper dose of (-)deprenyl (D) to prolong the life spans of rats explains discrepancies among different studies in the past.

  Annals of the New York Academy of Sciences 20060501

• Selegiline slows the progression of the symptoms of Parkinson disease.

  Neurology 20060425

• Patient page. Slowing down a 'slow' movement disorder: selegiline's benefit in treating Parkinson disease.

  Neurology 20060425

• Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].

  The Journal of pharmacology and experimental therapeutics 20060401

• Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.

  The Journal of clinical psychiatry 20060401

• Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats.

  European journal of pharmacology 20060227

• The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.

  Journal of pharmaceutical and biomedical analysis 20060224

• Effects of selegiline on antioxidant systems in the nigrostriatum in rat.

  Journal of neural transmission (Vienna, Austria : 1996) 20060201

• Modulation of brain mitochondrial function by deprenyl.

  Neurochemistry international 20060201

• Clomipramine and selegiline: do they influence impulse control?

  Journal of veterinary pharmacology and therapeutics 20060201

• H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice.

  The European journal of neuroscience 20060201

• Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins.

  Biochemical and biophysical research communications 20060120

• Acute and delayed effect of (-) deprenyl and (-) 1-phenyl-2-propylaminopentane (PPAP) on the serotonin content of peritoneal cells (white blood cells and mast cells).

  Cell biochemistry and function 20060101

• Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats.

  Physiological research 20060101

• Chronic exposure of rats to cognition enhancing drugs produces a neuroplastic response identical to that obtained by complex environment rearing.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20060101

• Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.

  Progress in neuro-psychopharmacology & biological psychiatry 20060101

• A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys.

  Psychopharmacology 20060101

• Efficacy and safety of high-dose cabergoline in Parkinson's disease.

  Acta neurologica Scandinavica 20060101

• Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.

  British journal of pharmacology 20060101

• Effect of nerodilol, carvone and anethole on the in vitro transdermal delivery of selegiline hydrochloride.

  Die Pharmazie 20060101

• Treatment of primary progressive freezing of gait with high doses of selegiline.

  Clinical neuropharmacology 20060101

• Persistent sexual side effects after SSRI discontinuation.

  Psychotherapy and psychosomatics 20060101

• Quality of life in Parkinson's disease--Indian scenario.

  The Journal of the Association of Physicians of India 20060101

• Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.

  The Journal of clinical psychiatry 20060101

• Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: predicting cocaine-dependent treatment attrition.

  The Journal of neuropsychiatry and clinical neurosciences 20060101

• First depression patch approved.

  FDA consumer 20060101

• [Interaction of pyruvate kinase with isatin and deprenyl].

  Biomeditsinskaia khimiia 20060101

• Therapeutic options for cognitive decline in senior pets.

  Journal of the American Animal Hospital Association 20060101

• Selegiline induces neuronal phenotype and neurotrophins expression in embryonic stem cells.

  Rejuvenation research 20060101

• Isatin interaction with glyceraldehyde-3-phosphate dehydrogenase, a putative target of neuroprotective drugs: partial agonism with deprenyl.

  Journal of neural transmission. Supplementum 20060101

• Deprenyl: from chemical synthesis to neuroprotection.

  Journal of neural transmission. Supplementum 20060101

• Low dose (-)deprenyl is cytoprotective: it maintains mitochondrial membrane potential and eliminates oxygen radicals.

  Life sciences 20051205

• A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline.

  Pharmacology, biochemistry, and behavior 20051201

• Dementia.

  Clinical evidence 20051201

• Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons.

  Brain research. Molecular brain research 20051130

• Deprenyl enhances the striatal neuronal damage produced by quinolinic acid.

  Brain research. Molecular brain research 20051118

• Increased cell-cell adhesion, a novel effect of R-(-)-deprenyl.

  Journal of neural transmission (Vienna, Austria : 1996) 20051101

• Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl.

  Molecular pharmacology 20051101

• Selegiline protects against recognition memory impairment induced by neonatal iron treatment.

  Experimental neurology 20051101

• Harmane inhibits serotonergic dorsal raphe neurons in the rat.

  Psychopharmacology 20051101

• Parkinson's disease and sleep.

  Neurologic clinics 20051101

• Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.

  Expert review of neurotherapeutics 20051101

• Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.

  Expert review of neurotherapeutics 20051101

• Would caregivers of Alzheimer disease patients involve their relative in a decision to use an AD-slowing medication?

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20051101

• 2-Phenylethylamine in combination with l-deprenyl lowers the striatal level of dopamine and prolongs the duration of the stereotypy in mice.

  Pharmacology, biochemistry, and behavior 20051101

• Effects of monoamine oxidase inhibitors on methamphetamine-induced stereotypy in mice and rats.

  Neurochemical research 20051101

• Discriminative stimulus and reinforcing effects of p-fluoro-L-deprenyl in monkeys.

  Psychopharmacology 20051001

• Antidepressant-like effects of selegiline in the forced swim test.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20051001

• In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20051001

• Protein aggregation in retinal cells and approaches to cell protection.

  Cellular and molecular neurobiology 20050901

• Effects of selegiline alone or with donepezil on memory impairment in rats.

  European journal of pharmacology 20050822

• LED fluorescence spectroscopy for direct determination of monoamine oxidase B inactivation.

  Analytical biochemistry 20050815

• Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.

  Journal of clinical pharmacology 20050801

• Reexamination of the TEMPO Study.

  Archives of neurology 20050801

• Rasagiline.

  Nature reviews. Drug discovery 20050801

• Monoamine oxidase B inhibitors for early Parkinson's disease.

  The Cochrane database of systematic reviews 20050720

• Evidence for reduced arterial plasma input, prolonged lung retention and reduced lung monoamine oxidase in smokers.

  Nuclear medicine and biology 20050701

• Detection of N-monomethyl-lysine generated by metabolic transmethylation.

  Analytical and bioanalytical chemistry 20050601

• Contribution of L-3,4-dihydroxyphenylalanine metabolism to the inhibition of gluconeogenesis in rabbit kidney-cortex tubules.

  The international journal of biochemistry & cell biology 20050601

• Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients.

  Parkinsonism & related disorders 20050601

• Reversal of age-related deficits in object recognition memory in rats with l-deprenyl.

  Experimental gerontology 20050601

• Parkinson's disease.

  Clinical evidence 20050601

• Parkinson's disease. Diagnosis and the initiation of therapy.

  Minerva medica 20050601

• Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.

  Movement disorders : official journal of the Movement Disorder Society 20050501

• [A case of interval form of carbon monoxide poisoning with a remarkable recovery].

  Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20050501

• Mechanism of 1-methyl-4-phenylpyridinium-induced dopamine release from PC12 cells.

  Neurochemical research 20050501

• HPLC and HPLC-MS analysis of urinary N(epsilon)-monomethyl-lysine.

  Journal of chromatographic science 20050401

• [Role of R-(-)-deprenyl in adhesion of neuronal and non-neuronal cells].

  Orvosi hetilap 20050327

• 'Levodopa phobia': a new iatrogenic cause of disability in Parkinson disease.

  Neurology 20050308

• Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.

  Neuroscience research 20050301

• Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs.

  Progress in neuro-psychopharmacology & biological psychiatry 20050301

• Estimation of endogenous noradrenaline release in rat brain in vivo using [3H]RX 821002.

  Synapse (New York, N.Y.) 20050201

• The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.

  Acta neurologica Scandinavica 20050201

• Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia.

  The American journal of psychiatry 20050201

• Effects of high-dose selegiline on morphine reinforcement and precipitated withdrawal in dependent rats.

  Behavioural pharmacology 20050201

• Selegiline in the management of apathy following traumatic brain injury.

  Brain injury 20050201

• Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.

  Neurology 20050111

• Selegiline modifies the extinction of responding following morphine self-administration, but does not alter cue-induced reinstatement, reacquisition of morphine reinforcement, or precipitated withdrawal.

  Pharmacological research 20050101

• Molecular characterization of monoamine oxidase in zebrafish (Danio rerio).

  Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology 20050101

• Marked effect of liver and kidney function on the pharmacokinetics of selegiline.

  Clinical pharmacology and therapeutics 20050101

• Intracellular dopamine oxidation mediates rotenone-induced apoptosis in PC12 cells.

  Acta pharmacologica Sinica 20050101

• Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytriptamine turnover in the striatum.

  Neuroscience 20050101

• sgk1, a member of an RNA cluster associated with cell death in a model of Parkinson's disease.

  The European journal of neuroscience 20050101

• Other pharmacological treatments for motor complications and dyskinesias.

  Movement disorders : official journal of the Movement Disorder Society 20050101

• Dislocation of the glenoid fossa.

  Journal of shoulder and elbow surgery 20050101

• 'My involvement in aging research was just a series of coincidences' An interview with Kenichi Kitani. Interview by Sataro Goto.

  Biogerontology 20050101

• Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.

  Clinical neuropharmacology 20050101

• A rapid, sensitive electron-capture gas chromatographic procedure for analysis of metabolites of N-methyl,N-propargylphenylethylamine, a potential neuroprotective agent.

  Journal of pharmacological and toxicological methods 20050101

• Effect of I-deprenyl and gliclazide on oxidant stress/antioxidant status and dna damage in a diabetic rat model.

  Endocrine research 20050101

• Dose-dependency of life span prolongation of F344/DuCrj rats injected with (-)deprenyl.

  Biogerontology 20050101

• [Alzheimer's disease therapy--theory and practice].

  Wiadomosci lekarskie (Warsaw, Poland : 1960) 20050101

• Deprenyl, a therapeutic agent for Parkinson's disease, inhibits arsenic toxicity potentiated by GSH depletion via inhibition of JNK activation.

  Journal of toxicology and environmental health. Part A 20041201

• Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease.

  Medical science monitor : international medical journal of experimental and clinical research 20041201

• Treatment possibilities of Alzheimer's disease.

  Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20041201

• The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.

  Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20041201

• Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.

  Neurology 20041012

• A novel formulation of selegiline for the treatment of Parkinson's disease.

  Neurology 20041012

• Clinical trials of neuroprotection for Parkinson's disease.

  Neurology 20041012

• A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.

  Neurology 20041012

• Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.

  British journal of pharmacology 20041001

• Levodopa-responsive parkinsonism in hereditary spastic paraplegia with thin corpus callosum.

  Parkinsonism & related disorders 20041001

• In vitro confirmation of selegiline N-oxidation by flavin-containing monooxygenase in rat microsome using LC-ESI MS.

  Biological & pharmaceutical bulletin 20041001

• Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.

  European journal of pharmacology 20040919

• Pitfalls of animal model systems in ageing research.

  Best practice & research. Clinical endocrinology & metabolism 20040901

• Effects of repeated administration of Uncaria hooks on the acquisition and central neuronal activities in ethanol-treated mice.

  Journal of ethnopharmacology 20040901

• (-)-Deprenyl alleviates the degenerative changes induced in the neonatal rat spinal cord by CSF from amyotrophic lateral sclerosis patients.

  Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 20040901

• High-performance liquid chromatography/tandem mass spectrometry assay for the determination of 1-methyl-4-phenyl pyridinium (MPP+) in brain tissue homogenates.

  Journal of neuroscience methods 20040830

• 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B.

  Neuroscience letters 20040826

• Subthalamic deep brain stimulation masking possible malignant syndrome in Parkinson disease.

  Neurology 20040810

• Pharmacological aspects of (-)-deprenyl.

  Current medicinal chemistry 20040801

• Assessment of the N-oxidation of deprenyl, methamphetamine, and amphetamine enantiomers by chiral capillary electrophoresis: an in vitro metabolism study.

  Electrophoresis 20040801

• Selectivity of 7-alkoxycoumarins as probe substrates for rat hepatic cytochrome P450 forms is influenced by the substitution pattern on the coumarin nucleus.

  Xenobiotica; the fate of foreign compounds in biological systems 20040801

• Selegiline potentiates the effects of EGb 761 in response to ischemic brain injury.

  Neurochemistry international 20040701

• Selegiline, an MAO-B inhibitor, attenuates airway smooth muscle contraction in the rat trachea.

  The Journal of pharmacy and pharmacology 20040701

• Selegiline increases heme oxygenase-1 expression and the cytotoxicity produced by dopamine treatment of neuroblastoma SK-N-SH cells.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20040701

• Modulation of glucose uptake in glial and neuronal cell lines by selected neurological drugs.

  Toxicology letters 20040615

• Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline.

  Parkinsonism & related disorders 20040601

• Dementia.

  Clinical evidence 20040601

• Parkinson's disease.

  Clinical evidence 20040601

• 1-Benzyl-1,2,3,4-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases alpha-synuclein expression and causes nuclear damage in human dopaminergic cells.

  Journal of neuroscience research 20040515

• Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives.

  Progress in neuro-psychopharmacology & biological psychiatry 20040501

• Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase: a role in high glucose-induced apoptosis in retinal Müller cells.

  Investigative ophthalmology & visual science 20040501

• A 'cure' for Parkinson's disease: can neuroprotection be proven with current trial designs?

  Movement disorders : official journal of the Movement Disorder Society 20040501

• Inefficacy of selegiline in treatment of canine pituitary-dependent hyperadrenocorticism.

  Australian veterinary journal 20040501

• Comparison of the binding of the irreversible monoamine oxidase tracers, [(11)C]clorgyline and [(11)C]l-deprenyl in brain and peripheral organs in humans.

  Nuclear medicine and biology 20040401

• Cardiopulmonary effects of medetomidine, oxymorphone, or butorphanol in selegiline-treated dogs.

  Veterinary anaesthesia and analgesia 20040401

• Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.

  Movement disorders : official journal of the Movement Disorder Society 20040401

• Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs.

  Acta neuropathologica 20040301

• (-)-Deprenyl inhibits tyramine-induced noradrenaline release, but not tyramine-induced dopamine release or potassium-induced noradrenaline release, from rat brain synaptosomes.

  Pharmacological research 20040301

• Transdermal selegiline and intravenous cocaine: safety and interactions.

  Psychopharmacology 20040201

• l-Deprenyl prevents lipid peroxidation and memory deficits produced by cerebral ischemia in rats.

  Cellular and molecular neurobiology 20040201

• Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline.

  Neuroscience letters 20040130

• Positive effects of deprenyl and estradiol on spatial memory and oxidant stress in aged female rat brains.

  Neuroscience letters 20040116

• Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus.

  Neurotoxicology 20040101

• (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.

  Neurotoxicology 20040101

• Adverse effects of dopamine potentiation by long-term treatment with selegiline.

  Movement disorders : official journal of the Movement Disorder Society 20040101

• Chiral separation of deprenyl-N-oxide isomers by capillary electrophoresis using various cyclodextrin derivatives.

  Journal of chromatographic science 20040101

• [Prognosis in Alzheimer's disease].

  Nihon rinsho. Japanese journal of clinical medicine 20040101

• Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats.

  Neurotoxicity research 20040101

• Brain cholinesterases: III. Future perspectives of AD research and clinical practice.

  Medical hypotheses 20040101

• Effects of dopaminergic treatment on bladder function in Parkinson's disease.

  Neurourology and urodynamics 20040101

• In vitro formation of selegiline-N-oxide as a metabolite of selegiline in human, hamster, mouse, rat, guinea-pig, rabbit and dog.

  European journal of drug metabolism and pharmacokinetics 20040101

• [The effect of long-term administration of isatin and himantan to mice on sensitivity of brain monoamine oxidase B to inhibition by deprenyl in vivo and in vitro].

  Biomeditsinskaia khimiia 20040101

• Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial.

  Journal of child and adolescent psychopharmacology 20040101

• Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and L-dopa in MPTP-treated mice.

  Journal of neural transmission (Vienna, Austria : 1996) 20031201

• Analysis of benzene ethylamine derivatives in urine using the programmable dynamic liquid-phase microextraction (LPME) device.

  The Analyst 20031201

• The effects of chronic administration of inhibitors of flavin and quinone amine oxidases on imidazoline I(1) receptor density in rat whole brain.

  Annals of the New York Academy of Sciences 20031201

• Relationship between imidazoline(2) sites and monoamine oxidase.

  Annals of the New York Academy of Sciences 20031201

• Pro-apoptotic and anti-apoptotic molecules affecting pathways of signal transduction.

  Annals of the New York Academy of Sciences 20031201

• Parkinson's disease.

  Clinical evidence 20031201

• Reduced cardiovascular effects of methamphetamine following treatment with selegiline.

  Drug and alcohol dependence 20031124

• Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionising radiation and chemotherapy toxicity.

  British journal of cancer 20031117

• Transdermal selegiline: targeted effects on monoamine oxidases in the brain.

  Biological psychiatry 20031115

• L-Deprenyl as an inhibitor of menadione-induced permeability transition in liver mitochondria.

  Biochemical pharmacology 20031101

• Clinical inquiries. What is the best initial treatment of Parkinson's disease?

  The Journal of family practice 20031101

• Selegiline reduces N-methyl-D-aspartic acid induced perturbation of neurotransmission but it leaves NMDA receptor dependent long-term potentiation intact in the hippocampus.

  Journal of neural transmission (Vienna, Austria : 1996) 20031101

• A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.

  Journal of neural transmission (Vienna, Austria : 1996) 20031101

• A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.

  Journal of neural transmission (Vienna, Austria : 1996) 20031101

• Selegiline's neuroprotective capacity revisited.

  Journal of neural transmission (Vienna, Austria : 1996) 20031101

• L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.

  Neurology 20031014

• D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.

  Synapse (New York, N.Y.) 20031001

• A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation.

  Addiction (Abingdon, England) 20031001

• Pharmacologic treatment of Alzheimer's disease: an update.

  American family physician 20031001

• Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects.

  Prescrire international 20031001

• L-selegiline potentiates the cellular poly(ADP-ribosyl)ation response to ionizing radiation.

  The Journal of pharmacology and experimental therapeutics 20030901

• Selegiline long-term effects on brain acetylcholinesterase, (Na+,K+)-ATPase activities, antioxidant status and learning performance of aged rats.

  Pharmacological research 20030901

• Cytochrome P450-dependent metabolism of l-deprenyl in monkey (Cercopithecus aethiops) and C57BL/6 mouse brain microsomal preparations.

  Journal of neurochemistry 20030901

• Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems.

  Drug metabolism and disposition: the biological fate of chemicals 20030901

• Deprenyl blocks the aglycemia-induced depression of the synaptic transmission but not the ischemia-induced depression in neonatal rat spinal cord in vitro.

  Neuroscience research 20030901

• Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

  Neurology 20030812

• [Therapy for patients with early-stage Parkinson's disease].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20030810

• Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives.

  Neurochemical research 20030801

• Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture.

  Neuroscience research 20030801

• Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice.

  Journal of neural transmission (Vienna, Austria : 1996) 20030801

• Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.

  Journal of neural transmission (Vienna, Austria : 1996) 20030801

• Chiral characterization of deprenyl-N-oxide and other deprenyl metabolites by capillary electrophoresis using a dual cyclodextrin system in rat urine.

  Electrophoresis 20030801

• Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial.

  Progress in neuro-psychopharmacology & biological psychiatry 20030801

• Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats.

  Brain research 20030627

• Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons.

  Antioxidants & redox signaling 20030601

• An HPLC tracing of the enhancer regulation in selected discrete brain areas of food-deprived rats.

  Life sciences 20030509

• Enhancer substances: selegiline and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes.

  Life sciences 20030502

• Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B.

  Journal of neural transmission (Vienna, Austria : 1996) 20030501

• Environmental influence on recovery after brain lesions--experimental and clinical data.

  Journal of rehabilitation medicine 20030501

• Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons.

  Journal of neurocytology 20030501

• A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.

  Life sciences 20030425

• Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine.

  Synapse (New York, N.Y.) 20030401

• Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication.

  Journal of analytical toxicology 20030401

• Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.

  Parkinsonism & related disorders 20030301

• Safety of selegiline with cold medications.

  The Annals of pharmacotherapy 20030301

• [Biomedical imaging in pharmacology with nuclear medical imaging methodologies: positron emission tomography (PET) and single photon emission computed tomography (SPECT)].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20030301

• Monoamine oxidase inhibitors--is it time to up the TEMPO?

  The Lancet. Neurology 20030301

• Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: association with improvement of cardiac function.

  European journal of pharmacology 20030214

• l-Deprenyl metabolism by the cytochrome P450 system in monkey (Cercopithecus aethiops) liver microsomes.

  Xenobiotica; the fate of foreign compounds in biological systems 20030201

• A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.

  The Journal of clinical psychiatry 20030201

• The relevance of preclinical studies for the treatment of Parkinson's disease.

  Journal of neurology 20030201

• A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation.

  Biological psychiatry 20030115

• Protective effects of selegiline and desmethylselegiline against N-methyl-D-aspartate-induced rat retinal damage.

  European journal of pharmacology 20030101

• Evidence for dopamine-derived hydroxyl radical formation in the nigrostriatal system in response to axotomy.

  Free radical biology & medicine 20030101

• Selegiline for Alzheimer's disease.

  The Cochrane database of systematic reviews 20030101

• In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography.

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20030101

• Selegiline-transdermal--Somerset: Emsam.

  Drugs in R&D 20030101

• Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion.

  Neurobiology of aging 20030101

• Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues.

  The Journal of pharmacy and pharmacology 20030101

• Neuroprotection for Parkinson's disease: prospects and promises.

  Annals of neurology 20030101

• Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease.

  Dementia and geriatric cognitive disorders 20030101

• Neurostimulatory and antioxidative effects of L-deprenyl in aged rat brain regions.

  Biogerontology 20030101

• Clinical pharmacokinetics of cabergoline.

  Clinical pharmacokinetics 20030101

• Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study.

  Clinical neuropharmacology 20030101

• Noncholinergic treatment options for Alzheimer's disease.

  The Journal of clinical psychiatry 20030101

• Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease.

  Journal of neural transmission. Supplementum 20030101

• Antioxidant properties of newly synthesized N-propargylamine derivatives of nitroxyl: a comparison with deprenyl.

  Polish journal of pharmacology 20030101

• Neuroprotective effect of deprenyl in sensory neurons of axotomized dorsal root ganglion.

  Clinical neuropharmacology 20030101

• [Mild cognitive impairment].

  Ryoikibetsu shokogun shirizu 20030101

• [Effect of a new antiparkinsonian drug himantane on monoamine oxidase activity].

  Eksperimental'naia i klinicheskaia farmakologiia 20030101

• Medical treatment of hyperadrenocorticism in the dog.

  Australian veterinary journal 20030101

• Detection, quantification, metabolism, and behavioral effects of selegiline in horses.

  Veterinary therapeutics : research in applied veterinary medicine 20030101

• Selegiline enhances erectile activity induced by dopamine injection in the paraventricular nucleus of the hypothalamus in anesthetized rats.

  International journal of impotence research 20021201

• [Long-term treatment of Parkinson's disease patients with selegiline hydrochloride (FPF 1100): outcome of 5-year treatment].

  No to shinkei = Brain and nerve 20021201

• Recent advances in Parkinson's disease.

  Ideggyogyaszati szemle 20021120

• Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.

  The American journal of psychiatry 20021101

• Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits.

  Neuropharmacology 20021101

• Effects of short- and long-term (--)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain.

  Brain research 20021025

• PET imaging of monoamine oxidase B in peripheral organs in humans.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20021001

• Quantitative analysis of selegiline and three metabolites (N-desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry.

  Journal of analytical toxicology 20021001

• Practical importance of neuroprotection in Parkinson's disease.

  Journal of neurology 20021001

• 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged.

  Life sciences 20020913

• Effects of selegiline (L-deprenyl) during smoking and short-term abstinence.

  Psychopharmacology 20020901

• Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man.

  Xenobiotica; the fate of foreign compounds in biological systems 20020901

• Selegiline: a second look. Six years later: too risky in Parkinson's disease.

  Prescrire international 20020801

• Selegiline transdermal system Somerset.

  Current opinion in investigational drugs (London, England : 2000) 20020801

• Effects of (-)deprenyl (selegiline) on acetylcholinesterase and Na(+),K(+)-ATPase activities in adult rat whole brain.

  Pharmacological research 20020801

• Treatment of an acromegalic cat with the dopamine agonist L-deprenyl.

  Australian veterinary journal 20020801

• [The usefulness of dopaminergic drugs in traumatic brain injury].

  Revista de neurologia 20020801

• Neurological effects of psychopharmacological agents.

  Seminars in clinical neuropsychiatry 20020701

• Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.

  European journal of clinical pharmacology 20020701

• Smoking cessation and panic attacks: a report of 2 cases.

  The Journal of clinical psychiatry 20020701

• Electroencephalographic activation by tacrine, deprenyl, and quipazine: cholinergic vs. non-cholinergic contributions.

  European journal of pharmacology 20020628

• Effects of selegiline, phenylpropanolamine, or a combination of both on physiologic and behavioral variables in healthy dogs.

  American journal of veterinary research 20020601

• Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results.

  Journal of occupational and environmental medicine 20020501

• (-)-Deprenyl fails to promote axonal regeneration of retinal ganglion cells in vitro and in vivo.

  Cell and tissue research 20020501

• The effect of deprenyl washout in patients with long-standing Parkinson's disease.

  Journal of neural transmission (Vienna, Austria : 1996) 20020501

• Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.

  Annals of neurology 20020501

• Modulation of neuroendocrine--immune signaling by L-deprenyl and L-desmethyldeprenyl in aging and mammary cancer.

  Mechanisms of ageing and development 20020430

• Why (--)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects.

  Mechanisms of ageing and development 20020430

• Pharmacological interventions in aging and age-associated disorders: potentials of propargylamines for human use.

  Annals of the New York Academy of Sciences 20020401

• Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation.

  International journal of geriatric psychiatry 20020401

• [Serotonin syndrome: report of a fatal case and review of the literature].

  Revista clinica espanola 20020401

• [The evolution of use of anti-Parkinson drugs in Spain].

  Revista de neurologia 20020401

• Inhibition of human LDL oxidation by the neuroprotective drug l-deprenyl.

  Neurological research 20020301

• Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20020301

• Treatment of periodic limb movements in sleep with selegiline HCl.

  Movement disorders : official journal of the Movement Disorder Society 20020301

• Effect of R-(-)-deprenyl and harmaline on dopamine- and peroxynitrite-induced membrane permeability transition in brain mitochondria.

  Neurochemical research 20020301

• Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.

  Parkinsonism & related disorders 20020301

• Neuroprotective actions of selegiline.

  Journal of neuroscience research 20020201

• The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials.

  International journal of geriatric psychiatry 20020201

• Antiapoptotic effect of (-)-deprenyl in rat kidney after ischemia-reperfusion.

  Medical science monitor : international medical journal of experimental and clinical research 20020201

• Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum.

  Toxicology 20020125

• The influence of metabolism on the MAO-B inhibitory potency of selegiline.

  Current medicinal chemistry 20020101

• Effect of repeated treatment with high doses of selegiline on behaviour, striatal dopaminergic transmission and tyrosine hydroxylase mRNA levels.

  Naunyn-Schmiedeberg's archives of pharmacology 20020101

• Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice.

  Methods and findings in experimental and clinical pharmacology 20020101

• Morphometric evaluation of the neuroprotective effect of deprenyl on postaxotomic motor neuron losses.

  Clinical neuropharmacology 20020101

• [Study of the tissue and subcellular distribution of isatin-binding proteins with optical biosensor].

  Voprosy meditsinskoi khimii 20020101

• Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline.

  Clinical neuropharmacology 20020101

• MAO-B inhibitors for the treatment of Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20020101

• [Monoamine oxidase inhibitors: prospects for the use in clinical practice].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20020101

• The multiple actions of selegiline.

  Proceedings of the Western Pharmacology Society 20020101

• Monoamine oxidase inhibitors: a new generation.

  Psychopharmacology bulletin 20020101

• Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy.

  The Cochrane database of systematic reviews 20020101

• [Effectiveness and tolerability of selegiline in the treatment of pathological cerebral involutions].

  La Clinica terapeutica 20020101

• Zonisamide has beneficial effects on Parkinson's disease patients.

  Neuroscience research 20011201

• Investigating potential anxiolytic, antidepressant and memory enhancing activity of deprenyl.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20011201

• Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.

  Neurology 20011113

• Chronic daily administration of selegiline and EGb 761 increases brain's resistance to ischemia in mice.

  Brain research 20011102

• (-)-D-Deprenyl attenuates apoptosis in experimental brain ischaemia.

  European journal of pharmacology 20011102

• CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.

  Drug metabolism and disposition: the biological fate of chemicals 20011101

• The effects of oral selegiline hydrochloride on learning and training in the dog: a psychobiological interpretation.

  Progress in neuro-psychopharmacology & biological psychiatry 20011101

• Role of monoamine oxidase inhibition and monoamine depletion in fenfluramine-induced neurotoxicity and serotonin release.

  Pharmacology & toxicology 20011101

• Future of neuroprotection in Parkinson's disease.

  Parkinsonism & related disorders 20011001

• Incorporation of selegiline metabolites into hair after oral selegiline intake.

  Journal of analytical toxicology 20011001

• Medical treatment of canine pituitary-dependent hyperadrenocorticism (Cushing's disease).

  The Veterinary clinics of North America. Small animal practice 20010901

• Simultaneous determination of selegiline-N-oxide, a new indicator for selegiline administration, and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry.

  Journal of chromatography. B, Biomedical sciences and applications 20010805

• Inhibition of rat liver microsomal CYP1A2 and CYP2B1 activity by N-(2-heptyl)-N-methyl-propargylamine and by N-(2-heptyl)-propargylamine.

  Drug metabolism and disposition: the biological fate of chemicals 20010801

• [Parkinson's disease].

  Nihon rinsho. Japanese journal of clinical medicine 20010801

• Changes in vascular alpha 1- and alpha 2-adrenoceptor responsiveness by selegiline treatment.

  Fundamental & clinical pharmacology 20010801

• Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.

  Neurology 20010724

• Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.

  Neurology 20010724

• Current advances in Parkinson's disease.

  Trends in neurosciences 20010701

• Freezing of gait in PD: prospective assessment in the DATATOP cohort.

  Neurology 20010626

• Oxygen inhalation enhances striatal dopamine metabolism and monoamineoxidase enzyme inhibition prevents it: a microdialysis study.

  European journal of pharmacology 20010622

• Advances in managing Parkinson's disease.

  Hospital practice (1995) 20010615

• PET with 11C-deuterium-deprenyl and 18F-FDG in focal epilepsy.

  Acta neurologica Scandinavica 20010601

• The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.

  Neurobiology of disease 20010601

• Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks.

  Pharmacology & toxicology 20010601

• Rescue of dying neurons by (R)-deprenyl in the MPTP-mouse model of Parkinson's disease does not include restoration of neostriatal dopamine.

  Annals of the New York Academy of Sciences 20010601

• Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.

  Journal of neurology 20010601

• [Parkinson patients. Normal life expectancy with selegiline?].

  MMW Fortschritte der Medizin 20010528

• Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain.

  Life sciences 20010504

• Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.

  Bioorganic & medicinal chemistry 20010501

• CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.

  European journal of clinical pharmacology 20010501

• Monoamine oxidase assays.

  Current protocols in pharmacology 20010501

• L-Deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP(+) and beta-carbolinium: a microdialysis study in rats.

  Neuroscience letters 20010420

• Selective inhibition of MAO-B through chronic low-dose (R)-deprenyl treatment in C57BL/6 mice has no effect on basal neostriatal dopamine levels.

  Experimental neurology 20010401

• Attenuation of paraquat-induced dopaminergic toxicity on the substantia nigra by (-)-deprenyl in vivo.

  Toxicology and applied pharmacology 20010401

• Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.

  European journal of clinical pharmacology 20010401

• Deprenyl stimulates the efflux of monoamines from the rat hypothalamus in vitro.

  Brain research bulletin 20010401

• Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: a possible antioxidant strategy.

  Annals of the New York Academy of Sciences 20010401

• Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid.

  The Journal of biological chemistry 20010330

• L-dopa and selegiline for tyrosine hydroxylase deficiency.

  The Journal of pediatrics 20010301

• Parkinson's disease therapy: treatment of early and late disease.

  Chinese medical journal 20010301

• Eldepryl prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral neuronal apoptosis in mice.

  Chinese medical journal 20010301

• SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.

  Brain research 20010223

• Selective inhibition of amine oxidases differently potentiate the hypophagic effect of benzylamine in mice.

  European journal of pharmacology 20010209

• Selegiline combined with enriched-environment housing attenuates spatial learning deficits following focal cerebral ischemia in rats.

  Experimental neurology 20010201

• The economic consequences of a drug-drug interaction.

  Journal of clinical psychopharmacology 20010201

• Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs.

  Acta neuropathologica 20010201

• Possible applications for dopaminergic agents following traumatic brain injury: part 2.

  The Journal of head trauma rehabilitation 20010201

• Selegiline completely restores choline acetyltransferase activity deficits in simian immunodeficiency infection.

  European journal of pharmacology 20010105

• Different sensitivity of mitochondrial and cytosolic monoamine oxidases to in vivo but not in vitro inhibition by specific irreversible inhibitors.

  Medical science monitor : international medical journal of experimental and clinical research 20010101

• Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Freezing of gait in patients with advanced Parkinson's disease.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion.

  Neurochemical research 20010101

• [Current strategies of pathogenetic therapy of Alzheimer's disease].

  Vestnik Rossiiskoi akademii meditsinskikh nauk 20010101

• Effect of longevity treatment with (-)deprenyl on lifespan and sexual behavior in female rats.

  Neurobiology (Budapest, Hungary) 20010101

• Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.

  CNS drug reviews 20010101

• Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• [The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trials].

  Neurologia i neurochirurgia polska 20010101

• The effect of low oral doses of (-)-deprenyl and its metabolites on DSP-4 toxicity.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Pharmacological options for the treatment of Tourette's disorder.

  Drugs 20010101

• Selegiline treatment facilitates recovery after stroke.

  Neurorehabilitation and neural repair 20010101

• A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting.

  Veterinary therapeutics : research in applied veterinary medicine 20010101

• [Dopaminergic agonists in the treatment of Parkinson's disease].

  Revue medicale de Bruxelles 20001201

• Antioxidant activity of the monoamine oxidase B inhibitor lazabemide.

  Biochemical pharmacology 20000901

• A hypertensive reaction induced by concurrent use of selegiline and dopamine.

  The Annals of pharmacotherapy 20000901

• Adverse drug reactions to selegiline: a review of the French pharmacovigilance database.

  Clinical neuropharmacology 20000101

• The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.

  Journal of neural transmission (Vienna, Austria : 1996) 20000101

• Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.

  European psychiatry : the journal of the Association of European Psychiatrists 19991001

• Effect of selegiline on cognitive functions in Parkinson's disease.

  The Journal of the Association of Physicians of India 19990801

• Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 19990601

• Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.

  Movement disorders : official journal of the Movement Disorder Society 19990301

• Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline).

  Journal of neural transmission. Supplementum 19980101

• Experience with tranylcypromine in early Parkinson's disease.

  Journal of neural transmission. Supplementum 19980101

• Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.

  Journal of neurology, neurosurgery, and psychiatry 19970801

• The anticonvulsant effect of deprenyl on pentylenetetrazol-induced seizures in Lewis rats.

  The International journal of neuroscience 19970801

• Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome.

  Journal of clinical psychopharmacology 19970201

• Absence of acute cocaine interactions with the MAO-B inhibitor selegiline.

  Drug and alcohol dependence 19950701

• Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites.

  Clinical pharmacology and therapeutics 19941201

• The MAO-B inhibitor deprenyl, but not the MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-chloroamphetamine.

  Brain research 19940711

• Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.

  Neurology 19931001

• End-of-dose dystonia in Parkinson's disease.

  Neurology 19931001

• Deprenyl in attention deficit associated with Tourette's syndrome.

  Archives of neurology 19930301

• Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline.

  Lancet (London, England) 19930227

• Selegiline and manic behavior in Parkinson's disease.

  Archives of neurology 19921201

• In vivo and in vitro pharmacologic profile of two new irreversible MAO-B inhibitors: MDL 72,974A and fluorodeprenyl.

  Annals of the New York Academy of Sciences 19920511

• Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging.

  Neurology 19920301

• Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.

  The Journal of pharmacology and experimental therapeutics 19911101

• Improvement of cognitive function by MAO-B inhibitor L-deprenyl in aged rats.

  Pharmacology, biochemistry, and behavior 19910601

• A review of the pharmacology of selegiline.

  Acta neurologica Scandinavica. Supplementum 19910101

• Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage.

  International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 19910101

• Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans.

  Advances in neurology 19900101

• The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

  Science (New York, N.Y.) 19890804

• A possible L-deprenyl induced hypertensive reaction.

  Journal of clinical psychopharmacology 19890801

• Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase.

  Journal of neural transmission 19870101

• SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents.

  The Journal of pharmacology and experimental therapeutics 19870101

• Pharmacokinetic aspects of deprenyl effects.

  Polish journal of pharmacology and pharmacy 19840101

• Brain monoamine oxidase in suckling rabbits treated with organophosphorus compound. I. Acute intoxication.

  Acta physiologica Polonica 19840101

• Deprenyl (selegiline) in combination treatment of Parkinson's disease.

  Acta neurologica Scandinavica. Supplementum 19830101

• The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline.

  Biochemical pharmacology 19821115

• Inhibition of rabbit liver monoamine oxidase by nitro aromatic compounds.

  Biochemical pharmacology 19820815

• Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.

  Clinical and experimental neurology 19790101